% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • dooper55 dooper55 Nov 15, 2012 7:57 AM Flag

    Novel Treatment for Multiple Sclerosis

    GPR17-Targeting Compounds Identified by Omeros Promote Myelination
    -Remyelination May Provide a Novel Treatment for Multiple Sclerosis Patients- PR Newswire

    SEATTLE, Nov. 15, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have now been demonstrated to promote differentiation of the cells that form myelin in the central nervous system. Myelin is critical for the proper functioning of the nervous system, and demyelination is associated with multiple nervous system disorders, including multiple sclerosis (MS), traumatic brain or spinal cord injury, stroke and Alzheimer's disease. Using its proprietary high-throughput Cellular Redistribution Assay, Omeros believes that it alone has identified compounds that interact with GPR17, an orphan G protein-coupled receptor (GPCR).

    "These data are very encouraging," stated Bruce Trapp, Ph.D., founder and chief scientific officer of Renovo Neural Inc. (RNI), chairman of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic, and professor of neurosciences at Case Western Reserve University. "There are no approved remyelinating therapeutics, and the compounds under development by Omeros could lead to the first oral agents able to stimulate sufficient remyelination to restore neural function. This would represent a breakthrough in the treatment of currently irreversible demyelinating diseases, such as MS and other devastating myelin-related disorders." The data were generated through Omeros' collaboration with RNI, a company focused on remyelination research to accelerate drug development for demyelinating neural diseases.

    "GPR17 represents one of Omeros' unlocked GPCRs that we are advancing through medicinal chemistry," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The biology of the receptor – its strong link to remyelination – has been well documented, and Omeros now has identified over 90 compounds that functionally affect its signaling, and many of these are highly potent. These compounds are drawn from multiple classes of structurally diverse and tractable small-molecules, enabling the development of proprietary drugs that could restore function in patients faced with severely progressive or traumatic demyelinating neural disorders."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ...HAW!!!...desperate situations call for desperate measures, huh?!...HAW!...yeah, everybody's looking around wondering why OMER paid 4 MILLION dollars to a whistleblower just BEFORE the trial is to start but just AFTER the judge denies OMER's request to EXCLUDE NIH witness testimony...

      ...hmmmmm...QUICK!...what've we got on the GPR shelf?!!...okay, okay!!!...yeah, that's a good one!...use it!... put y'alls' minds at rest and stop paying attention to what might have been in that NIH testimony, ya'hear?...HAW, HAW, HAW!!!!....

      Sentiment: Strong Sell

8.72+0.20(+2.35%)Oct 24 4:00 PMEDT